Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy

Annals of the Rheumatic Diseases

Volumn 71, Issue 12, 2012, Pages 2058-2059

  Iwata, Shigeru ^a   Saito, Kazuyoshi ^a   Hirata, Shintaro ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD19 ANTIGEN; CORTICOSTEROID; IMMUNOGLOBULIN G4; PROTEIN KINASE SYK; RITUXIMAB;

ADULT; ANTIGEN EXPRESSION; B LYMPHOCYTE; BLOOD PROTEIN DISORDER; CASE REPORT; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; HUMAN; IMMUNOGLOBULIN G4 RELATED DISEASE; LETTER; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MEDICAL HISTORY; MEMORY CELL; MOLECULAR DYNAMICS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ADRENAL CORTEX HORMONES; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PLASMA CELLS;

EID: 84868459306     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201657     Document Type: Letter

References (10)

1. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-8.
2. Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009;68:1310-15.
3. Tanaka A, Moriyama M, Nakashima H, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheum 2012;64:254-63.
4. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993;90:3730-4.
5. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012;22:21-30.
6. Iwata S, Yamaoka K, Niiro H, et al. Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. J Allergy Clin Immunol 2012;129:1594-601.
7. Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010;62:1755-62.
8. Deng GM, Liu L, Bahjat FR, et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010;62:2086-92.
9. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12.
10. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113:3154-60.